MedCost Clear Cost calculator

Drugs / Skyrizi

Skyrizi cost

risankizumab-rzaa · AbbVie. Every official price for Skyrizi, side by side, with who pays it.

Short answer

We found no list price published by AbbVie. Medicare Part B pays up to $14.011 per mg for Skyrizi given by IV infusion or injection in a clinic (October 1, 2026 to December 31, 2026). Pharmacies paid an average of $22,795.09–$23,052.15 per pen or syringe (NADAC, Oct 21, 2026). At the FDA label dose of 150 mg at week 0, week 4, then every 12 weeks (an example), one dose (1 × 150 mg pen) comes to $22,795.09 at the average pharmacy acquisition cost. In 2024, Medicare Part D spent $2.5 billion on Skyrizi, an average of $20,459.66 per prescription fill before rebates (CMS). In Medicare Part D, the yearly out-of-pocket limit is $2,100 in 2026 and $2,400 in 2027.136945

Source: FDA, CMS, data.medicaid.gov (NADAC) and Medicare.gov · checked Nov 15, 2026

Skyrizi: the official numbers, by situation

PriceAmountWhose price, and who it applies toDate
List price Not published We found no list price published by AbbVie. —
Pharmacy cost (NADAC)
one dose: 1 × 150 mg pen (FDA label dose, an example)
$22,795.093 What pharmacies pay on average (CMS survey). Not a patient price. Oct 21, 2026
Medicare Part B payment limit
per mg, Skyrizi given by IV infusion or injection in a clinic
$14.0111 What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. October 1, 2026 – December 31, 2026

On Medicare drug coverage: 5,386 of 5,492 Part D plans list Skyrizi for 2027 (98%), and 98% of those require prior authorization, in CMS's formulary file published Oct 15, 2026.18 By year and tier

None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.

FDA approval

Every official price

PriceAmountWhat it isDate
Maker's list price (WAC) Not published We found no current list price on AbbVie's own pages, so we do not show one. —
Medicare Part B payment limit
Skyrizi given by IV infusion or injection in a clinic (risankizumab-rzaa) · HCPCS J2327
$14.0111 Per 1 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. October 1, 2026 – December 31, 2026
Pharmacy acquisition cost (NADAC)
Skyrizi 150 mg/mL pen
$22,795.093 Per pen or syringe ($22,795.09 per mL × 1 mL). The national average price pharmacies pay to buy it. Oct 21, 2026
Pharmacy acquisition cost (NADAC)
Skyrizi 150 mg/mL syringe
$22,924.373 Per pen or syringe ($22,924.37 per mL × 1 mL). The national average price pharmacies pay to buy it. Oct 21, 2026
Pharmacy acquisition cost (NADAC)
Skyrizi 180 mg/1.2 mL on-body
$23,052.153 Per pen or syringe ($19,210.13 per mL × 1.2 mL). The national average price pharmacies pay to buy it. Oct 21, 2026
Pharmacy acquisition cost (NADAC)
Skyrizi 360 mg/2.4 mL on-body
$22,962.523 Per pen or syringe ($9,567.72 per mL × 2.4 mL). The national average price pharmacies pay to buy it. Oct 21, 2026

These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below. CMS notes that a code's presence in its payment file does not by itself mean Medicare covers the drug.2

What Skyrizi costs at the FDA label dose (example)

In the FDA label section "Moderate-to-Severe Plaque Psoriasis", the dose is 150 mg at week 0, week 4, then every 12 weeks.67 We use it only to show the math with official prices. It is an example, not a dosing recommendation: your dose is your doctor's decision, and other uses on the label have other doses.

150 mg pen prices: NADAC effective Oct 21, 2026. FDA label version 180 (Oct 23, 2026).

PeriodAt pharmacy acquisition cost (NADAC)
One dose
1 × 150 mg pen: 1 pen
$22,795.093
First 52 weeks
5 × 150 mg pen: doses at weeks 0, 4, 16, 28, 40
$113,975.453

How we count: NADAC $22,795.09 per 150 mg pen (Skyrizi 150 mg/mL pen) times the count. None of these is what you pay at the counter: NADAC is what pharmacies pay to buy the drug.

What Medicare spent on Skyrizi in 2024

CMS publishes what Part D spent on each drug each year. Its spending is the gross drug cost, which includes what Medicare, the plan and the patient paid,11 and it does not reflect manufacturers' rebates.12 CMS lists Skyrizi in 3 rows; together they come to $2.5 billion over 121,579 prescription fills, $20,459.66 per fill.

Medicare Part D, calendar year 2024 (CMS Medicare Part D Spending by Drug, checked Nov 15, 2026).

Product (as CMS lists it)Total spendingFillsPeoplePer fillPer person
Skyrizi On-Body $390.6 million9 19,225 4,897 $20,316.2614 $79,759.0415
Skyrizi Pen $1.8 billion9 85,713 27,003 $20,782.0814 $65,966.5315
Skyrizi*16 $315.6 million9 16,641 5,557 $18,964.6414 $56,791.5315

For doses given in a clinic and paid under Part B, CMS's spending is the full value of the drug, including the Medicare payment and what the patient owed.13

Medicare Part B, calendar year 2024 (CMS Medicare Part B Spending by Drug, checked Nov 15, 2026).

HCPCS codeTotal spendingClaimsPeoplePer claimPer person
J2327
Injection, risankizumab-rzaa, intravenous, 1 mg
$76.7 million10 8,485 3,490 $9,041.86 $21,982.86

These are totals and averages across everyone in Medicare who used the drug, not a price for one person. Averages per person depend on how long and how much each person used it.

How many Medicare Part D plans list Skyrizi

Every Medicare drug plan in CMS's formulary file (standalone drug plans and Medicare Advantage plans with drug coverage). A plan counts when its drug list has at least one form or strength. Matched by RxNorm code and checked against the FDA NDC Directory. Plan counts, not people; to see your own plan's rules use Medicare Plan Finder.

Plan yearPlans that list itPrior auth.Step therapyQuantity limitLowest tier (plans)
2026 5,413 of 5,49617
98%
5,30705,127 tier 1: 157 · tier 2: 2 · tier 4: 50 · tier 5: 5,204
2027 5,386 of 5,49218
98%
5,28305,123 tier 1: 122 · tier 2: 1 · tier 4: 46 · tier 5: 5,217
2026: CMS file 2026_20260916.zip, published Sep 23, 2026 · 2027: CMS file 2027_20261008.zip, published Oct 15, 2026.

Being on a plan's list is not a price: what you pay depends on the tier and your plan. Each plan can divide its tiers in different ways. What prior authorization, step therapy and tiers mean.

Skyrizi's Medicare Part B payment limit, quarter by quarter

HCPCS J2327 (risankizumab-rzaa, per 1 mg), from each quarter's CMS ASP payment limit file. The limit is what Part B pays from; it applies when Skyrizi is given in a clinic and paid under Part B.

QuarterPayment limit per 1 mg
January–March 2025$15.08119
April–June 2025$14.85920
July–September 2025$14.84021
October–December 2025$14.94122
January–March 2026$14.93223
April–June 2026$14.59924
July–September 2026$14.53125
October–December 2026$14.01126

With Medicare

With commercial insurance or no insurance

Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.

Official sources for this page (26)
  1. “The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate whether Medicare covers a drug.”
  2. “Out-of-pocket limit Yearly $2,100 (in 2026).”
    Medicare.gov: Medicare costs · as of Oct 23, 2026
  3. “Out-of-Pocket Threshold: $2,100 Out-of-Pocket Threshold: $2,400”
  4. “150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.”
  5. “Injection: 150 mg/mL in each single-dose prefilled pen.”
  6. “BLA761105 ORIG-1 approved 20190423”
  7. “Skyrizi On-Body: Tot_Spndng_2024 390580004.22, Tot_Clms_2024 19225, Tot_Benes_2024 4897; Skyrizi Pen: Tot_Spndng_2024 1781294228.5, Tot_Clms_2024 85713, Tot_Benes_2024 27003; Skyrizi*: Tot_Spndng_2024 315590527.52, Tot_Clms_2024 16641, Tot_Benes_2024 5557”
  8. “J2327 Injection, risankizumab-rzaa, intravenous, 1 mg: Tot_Spndng_2024 76720174.47, Tot_Clms_2024 8485, Tot_Benes_2024 3490”
  9. “Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
  10. “The Part D spending metrics do not reflect any manufacturers' rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
  11. “Drug spending metrics for Part B drugs represent the full value of the product, including the Medicare payment and beneficiary liability.”
  12. “Part D drug spending divided by the number of prescription fills.”
  13. “Total Part D drug spending divided by the number of unique beneficiaries utilizing the drug during the benefit year.”
  14. “' * ' indicates that the average spending per dosage unit reflects multiple routes of administration of the drug”
  15. “J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 15.081, 20.000, ”
  16. “J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.859, 20.000, ”
  17. “J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.840, 20.000, ”
  18. “J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.941, 20.000, ”
  19. “J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.932, 20.000, ”
  20. “J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.599, 20.000, ”
  21. “J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.531, 20.000, ”
  22. “J2327, Inj risankizumab-rzaa 1 mg, 1 MG, 14.011, 20.000, ”

Did this page answer your question?